SecBot SecBot
SECBOTREPLAY Home › Report › PHAT

PHAT · Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the…

Phathom Pharmaceuticals · PRESS-RELEASE filed Apr 30, 2026 at 06:59 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed Apr 30, 2026 at 06:59 ET

Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS of -$0.37 missed the -$0.19 consensus. The company maintained FY 2026 guidance of $320-$345M revenue and expects operating profitability (ex-stock comp) starting Q3 2026. Prescription trends strengthened in late March/April, but the EPS miss and 'light to internal expectations' commentary temper the top-line beat.

  • Q1 2026 net revenue $58.3M vs $28.5M YoY (+104%), above $56.8M consensus
  • GAAP EPS -$0.37 vs consensus -$0.19 (miss of -94.7%)
  • Non-GAAP adjusted net loss per share -$0.18 vs -$1.07 YoY
  • FY 2026 guidance maintained: revenue $320-$345M, non-GAAP opex $235-$255M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access